Intranasal Human FGF-1 for Subjects With Parkinson's Disease
Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label, pilot study to evaluate the safety, tolerability and efficacy of two
dose levels of human FGF-1 administered intranasally to subjects with Parkinson's disease. A
low dose of 450 µg FGF-1 (6 µg/kg for a 75 kg subject) and a high dose of 900 µg FGF-1 (12
µg/kg for a 75 kg subject) will be studied sequentially.